Brief Summary
This study is investigating a new cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs treatment drug, RX108-A, to determine whether it is safe and effective for patients with locally advancedat a late stage, far along or metastatic solid tumors.
Intervention/Treatment
- Drug: RX108-A.
Inclusion Criteria
A patient will be eligible for study participation if the patient meets all of the following criteria:
- Signed Informed Consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment. Form.
- 18 years and over.
- Patients with locally advanced or metastatic solid tumors that have failed at least one standard of care therapy or were intolerant to, or have refused such treatment, are eligible.
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status of 0 or 1.
- Life expectancy of at least 3 months.
- Must agree to use adequate contraception (females and males).